Lite Strategy (LITS) Short-term Investments (2013 - 2024)
Lite Strategy (LITS) posted quarterly Short-term Investments of $20.0 million for Q3 2024, down 74.62% year-over-year from $78.8 million in Q4 2023, and down 42.26% quarter-over-quarter from $34.6 million in Q2 2024.
Lite Strategy (LITS) Short-term Investments (2013 - 2024) Analysis & Trends
Lite Strategy's Short-term Investments history runs 12 years deep, the most recent figure standing at $20.0 million for Q3 2024.
- In Q3 2024, Short-term Investments fell 74.62% year-over-year to $20.0 million; the TTM figure through Sep 2024 stood at $20.0 million (down 74.62% YoY), while the FY2024 annual figure was $34.6 million, down 58.66% from the prior year.
- Short-term Investments for Q3 2024 stood at $20.0 million, down from $34.6 million in the prior quarter.
- The five-year high for Short-term Investments was $173.2 million in Q4 2021, with the low at $20.0 million in Q3 2024.
- The 5-year median for Short-term Investments is $123.7 million (2022), against an average of $113.4 million.
- The sharpest annual moves came in 2020 and 2024: Short-term Investments surged 175.61% in 2020, then slumped 74.62% in 2024.
- Lite Strategy's Short-term Investments stood at $170.3 million in 2020, then rose by 1.72% to $173.2 million in 2021, then slumped by 34.61% to $113.3 million in 2022, then sank by 52.06% to $54.3 million in 2023, then slumped by 63.17% to $20.0 million in 2024.
- Business Quant data shows LITS's Short-term Investments at $20.0 million in Q3 2024, $34.6 million in Q2 2024, and $54.2 million in Q1 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Lite Strategy | 35.71 Mn | 28.17 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 20.00 Mn |
| Jun 30, 2024 | 34.64 Mn |
| Mar 31, 2024 | 54.20 Mn |
| Dec 31, 2023 | 54.30 Mn |
| Sep 30, 2023 | 78.80 Mn |
| Jun 30, 2023 | 83.79 Mn |
| Mar 31, 2023 | 103.20 Mn |
| Dec 31, 2022 | 113.26 Mn |
| Sep 30, 2022 | 123.71 Mn |
| Jun 30, 2022 | 137.51 Mn |
| Mar 31, 2022 | 157.93 Mn |
| Dec 31, 2021 | 173.20 Mn |
| Sep 30, 2021 | 129.88 Mn |
| Jun 30, 2021 | 144.88 Mn |
| Mar 31, 2021 | 154.88 Mn |
| Dec 31, 2020 | 170.27 Mn |
| Sep 30, 2020 | 165.18 Mn |
| Jun 30, 2020 | 170.30 Mn |
| Mar 31, 2020 | 85.36 Mn |
| Dec 31, 2019 | 95.24 Mn |